Von Leoprechting was previously the European sales director for the company's bio-discovery business. He has been with PerkinElmer in a variety of technology, sales, and marketing leadership roles since PerkinElmer acquired his previous employer, Packard BioScience, in 2002.
Migrations: Dec 5, 2008
CytRx announced that week that Joseph Rubinfeld, a member of the company’s board of directors, has accepted the additional responsibility of chief scientific advisor.
Rubinfeld was previously the vice president and director of research and development for Bristol-Myers’ international division. He was among the four co-founders of Amgen, and founded SuperGen, where he served as CEO, president, and chief scientific officer.
BrainCells announced this week the appointment of David Thompson to its board of directors.
Thompson’s 30-year career at Eli Lilly and its affiliates culminated in a stint as vice president of corporate strategy and business development. During his tenure at Eli Lilly, Thompson served as director of corporate new product planning and licensing, president, and general manager of Eli Lilly Canada; president and CEO of then-Lilly subsidiary IVAC Corporation; and vice president of pharmaceutical product management and licensing. He is currently executive chairman of Bayhill Therapeutics, and is a member of the board of directors for Anthera Pharmaceuticals.
PerkinElmer last week announced that Achim von Leoprechting has been appointed vice president and general manager of cellular imaging and analysis solutions.